ULTIMOVACS ASA ULTMF overview

Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS ("Zelluna"), the fully committed private placement (the "Private Placement"), and the intention to carry out a subsequent repair offering (the "Subsequent Offering") of up to 3,846,153 new shares at a subscription price per new share of NOK 2.60, directed towards shareholders of Ultimovacs or...

Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement (the "Private Placement" and together with the Business Combination, the "Transactions"). Please see the attached forms for information on the conditional allocation of shares in the Company to closely related parties of primary insiders in...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Ultimovacs ASA (OSE: ULTI) ("Ultimovacs" or the "Company") and Zelluna Immunotherapy AS ("Zelluna"), a privately held company pioneering the development of “off the shelf” T- Cell Receptor Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces...

Oslo, November 6, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its third quarter 2024 results today. Conference call and webcast scheduled for November 6, 2024, at 14:00 (CET). Link to webcast here . Third Quarter 2024 Business Update Highlights Ultimovacs implemented cash preservation initiatives during the second quarter of 2024. During the third quarter of 2024, additional cash preservation...

Oslo, October 31, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third quarter 2024 results, on Wednesday, November 6, 2024 . The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Wednesday, November 6, 2024. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post...

Oslo, October 25, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from Phase II FOCUS trial ( NCT05075122 ) have been published online on the preprint platform medRxiv. As previously reported , topline data readout demonstrated that adding UV1 to the standard of care pembrolizumab did not lead to clinical benefits in progression free survival or overall survival in the...

Oslo, September 11, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed with the investigators conducting the LUNGVAC trial ( NCT05344209 ) to discontinue patient recruitment. LUNGVAC is an investigator-initiated, randomized Phase II trial designed to assess the impact of UV1 in combination with the checkpoint inhibitor cemiplimab or pembrolizumab as first-line...

Oslo, September 9, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the presentation of updated data analysis from the UV1 Phase II NIPU trial ( NCT04300244 ), at the 2024 ESMO Congress . The NIPU trial evaluated the addition of UV1 telomerase vaccine to immunotherapy with ipilimumab and nivolumab compared with ipilimumab and nivolumab alone, as a second-line treatment for patients with...